iCAD (NASDAQ:ICAD – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $4.72 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
iCAD Stock Performance
iCAD stock opened at $2.29 on Monday. The stock has a 50-day moving average of $2.62 and a two-hundred day moving average of $2.04. The stock has a market cap of $60.78 million, a PE ratio of -17.62 and a beta of 1.95. iCAD has a one year low of $1.18 and a one year high of $3.78.
Wall Street Analyst Weigh In
Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, February 20th.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Further Reading
- Five stocks we like better than iCAD
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- How to Build the Ultimate Everything ETF Portfolio
- 3 Stocks to Consider Buying in October
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
